IL188031A0 - Use of thiazole derivatives and analogues in the treatment of cancer - Google Patents

Use of thiazole derivatives and analogues in the treatment of cancer

Info

Publication number
IL188031A0
IL188031A0 IL188031A IL18803107A IL188031A0 IL 188031 A0 IL188031 A0 IL 188031A0 IL 188031 A IL188031 A IL 188031A IL 18803107 A IL18803107 A IL 18803107A IL 188031 A0 IL188031 A0 IL 188031A0
Authority
IL
Israel
Prior art keywords
analogues
cancer
treatment
thiazole derivatives
thiazole
Prior art date
Application number
IL188031A
Other languages
English (en)
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of IL188031A0 publication Critical patent/IL188031A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL188031A 2005-07-21 2007-12-10 Use of thiazole derivatives and analogues in the treatment of cancer IL188031A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59562005P 2005-07-21 2005-07-21
SE0501721 2005-07-21
US74442206P 2006-04-07 2006-04-07
PCT/GB2006/002730 WO2007010273A2 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL188031A0 true IL188031A0 (en) 2011-08-01

Family

ID=37669179

Family Applications (2)

Application Number Title Priority Date Filing Date
IL188031A IL188031A0 (en) 2005-07-21 2007-12-10 Use of thiazole derivatives and analogues in the treatment of cancer
IL188163A IL188163A0 (en) 2005-07-21 2007-12-16 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL188163A IL188163A0 (en) 2005-07-21 2007-12-16 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Country Status (10)

Country Link
US (2) US20090156644A1 (enExample)
EP (2) EP1906956A2 (enExample)
JP (2) JP2009501776A (enExample)
KR (2) KR20080034436A (enExample)
AU (2) AU2006271375A1 (enExample)
CA (2) CA2614327A1 (enExample)
EA (2) EA200800302A1 (enExample)
IL (2) IL188031A0 (enExample)
NO (2) NO20076333L (enExample)
WO (2) WO2007010273A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024012A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008090327A1 (en) * 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
AR067769A1 (es) * 2007-08-03 2009-10-21 Betagenon Ab Derivado de ditiazol para el tratamiento del cancer
KR20100090250A (ko) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
CA2743756A1 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
KR100998572B1 (ko) * 2007-12-14 2010-12-07 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2011079036A1 (en) * 2009-12-22 2011-06-30 The Translational Genomics Research Institute Benzamide derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
EP2760856B1 (en) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
BR112022002815A2 (pt) * 2019-08-15 2022-05-10 Bayer Ag Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
EP4448492B1 (en) 2021-12-17 2026-03-04 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
JP7894535B2 (ja) 2023-02-28 2026-07-23 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345374A (en) * 1962-09-04 1967-10-03 Bayer Ag Certain oxathiazole and dithiazole derivatives
US3671537A (en) * 1969-06-05 1972-06-20 Gyogyszerkutato Intezet Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines
US4103018A (en) * 1976-10-12 1978-07-25 Schering Corporation 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto
HU191408B (en) * 1984-04-25 1987-02-27 Egis Gyogyszergyar,Hu Process for preparing new imino-thiazolidine derivatives
DD246541A1 (de) * 1986-01-27 1987-06-10 Univ Halle Wittenberg Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen
DD270072A1 (de) * 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US20040152667A1 (en) * 2002-10-23 2004-08-05 Hauske James R. 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
CN1972937A (zh) * 2004-04-30 2007-05-30 先灵公司 神经肽受体调节剂
RU2007103709A (ru) * 2004-07-01 2008-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Тиазолинонхинолины
EP1776112A4 (en) * 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
WO2006040050A1 (en) * 2004-10-14 2006-04-20 F.Hoffmann-La Roche Ag Quinazolinylmethylene thiazolinones as cdk1 inhibitors
CN100525929C (zh) * 2005-04-20 2009-08-12 郭文礼 喷水枪出水控制装置
CA2614098A1 (en) * 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator

Also Published As

Publication number Publication date
NO20076333L (no) 2008-04-01
CA2615752A1 (en) 2007-01-25
AU2006271375A1 (en) 2007-01-25
JP2009501776A (ja) 2009-01-22
EP1906955A2 (en) 2008-04-09
JP2009501775A (ja) 2009-01-22
US20090156644A1 (en) 2009-06-18
EA200800303A1 (ru) 2008-10-30
AU2006271375A2 (en) 2007-01-25
WO2007010281A2 (en) 2007-01-25
KR20080032096A (ko) 2008-04-14
US20090136472A1 (en) 2009-05-28
EA200800302A1 (ru) 2008-08-29
WO2007010273A3 (en) 2007-05-10
WO2007010273A2 (en) 2007-01-25
WO2007010281A3 (en) 2007-06-07
NO20076420L (no) 2008-04-09
EP1906956A2 (en) 2008-04-09
IL188163A0 (en) 2008-03-20
AU2006271383A1 (en) 2007-01-25
CA2614327A1 (en) 2007-01-25
KR20080034436A (ko) 2008-04-21

Similar Documents

Publication Publication Date Title
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL199609A0 (en) Antifolate agent combinations in the treatment of cancer
ZA200709751B (en) Thiazole compounds and methods of use
SI2100614T1 (sl) PROTITELO PROTI PDGFR-alfa ZA UPORABO PRI ZDRAVLJENJU TUMORJEV
IL192548A (en) Nitazoxanide and tizaxanide for use in the treatment of hepatitis c
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
ZA200804688B (en) Purine derivatives and methods of use thereof
PL1885380T3 (pl) Metaarsenian sodu do stosowania w leczeniu przerzutowych chorób nowotworowych
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
ZA200710104B (en) Thiazole derivatives and use thereof
ZA200709542B (en) Combination therapy in the treatment of cancer
ZA200800243B (en) Use of thiazole derivatives and analogues in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
PL1933840T3 (pl) Zastosowanie delmopinolu w leczeniu trądziku
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
GB2411834B (en) Composition for use in the treatment of dry skin conditions
PL1812072T3 (pl) Benzotiazolowe formulacje oraz ich zastosowanie
IL185575A0 (en) Benzoxazocines and their therapeutic use
HK1112852A (en) Use of thiazole derivatives and analogues in the treatment of cancer
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
GB0526292D0 (en) A composition for use in the treatment of a surface